Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 779Lung Neoplasms 345Ovarian Neoplasms 323Breast Neoplasms 279Fallopian Tube Neoplasms 159Triple Negative Breast Neoplasms 145Small Cell Lung Carcinoma 144Neoplasms 137Squamous Cell Carcinoma of Head and Neck 123Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 85Head and Neck Neoplasms 80Endometrial Neoplasms 76Uterine Cervical Neoplasms 72Esophageal Neoplasms 71Adenocarcinoma of Lung 70Neuroblastoma 55Central Nervous System Neoplasms 53Lymphoma, Large B-Cell, Diffuse 49Carcinoma 49Recurrence 48Brain Neoplasms 48Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Stomach Neoplasms 31

Interventions

Dexamethasone 3iniparib 2Ultrasonography 2Poly(ADP-ribose) Polymerase Inhibitors 2Calcium Dobesilate 2Blood Specimen Collection 2tislelizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1asparaginase erwinia chrysanthemi recombinant 1amminedichloro(2-methylpyridine)platinum(II) 1ZD4054 1Vincristine 1Sodium Chloride 1Rituximab 1Paclitaxel 1Narrow Band Imaging 1Methotrexate 1Mammography 1Lenalidomide 1Immune Checkpoint Inhibitors 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Cytarabine 1Cetirizine 1Carboplatin 1BNT162 Vaccine 1Asparaginase 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypersensitivity × Carboplatin × Clear all
NCT00929162 2012-08-07

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

AstraZeneca

Phase 2 Terminated
120 enrolled 8 charts

Hypersensitivity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡